JP2001521386A5 - - Google Patents

Download PDF

Info

Publication number
JP2001521386A5
JP2001521386A5 JP1998543387A JP54338798A JP2001521386A5 JP 2001521386 A5 JP2001521386 A5 JP 2001521386A5 JP 1998543387 A JP1998543387 A JP 1998543387A JP 54338798 A JP54338798 A JP 54338798A JP 2001521386 A5 JP2001521386 A5 JP 2001521386A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1998543387A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001521386A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK1998/000157 external-priority patent/WO1998046642A1/en
Publication of JP2001521386A publication Critical patent/JP2001521386A/ja
Publication of JP2001521386A5 publication Critical patent/JP2001521386A5/ja
Pending legal-status Critical Current

Links

JP54338798A 1997-04-15 1998-04-15 被修飾TNFα分子、このような被修飾TNFα分子をコードするDNA、並びにこのような被修飾TNFα分子及びDNAを具備するワクチン Pending JP2001521386A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK41897 1997-04-15
US4418797P 1997-04-24 1997-04-24
US60/044,187 1997-04-24
US0418/97 1997-04-24
PCT/DK1998/000157 WO1998046642A1 (en) 1997-04-15 1998-04-15 MODIFIED TNFα MOLECULES, DNA ENCODING SUCH MODIFIED TNFα MOLECULES AND VACCINES COMPRISING SUCH MODIFIED TNFα MOLECULES AND DNA

Publications (2)

Publication Number Publication Date
JP2001521386A JP2001521386A (ja) 2001-11-06
JP2001521386A5 true JP2001521386A5 (https=) 2005-11-24

Family

ID=8093298

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54338798A Pending JP2001521386A (ja) 1997-04-15 1998-04-15 被修飾TNFα分子、このような被修飾TNFα分子をコードするDNA、並びにこのような被修飾TNFα分子及びDNAを具備するワクチン

Country Status (29)

Country Link
US (1) US7118750B1 (https=)
EP (1) EP0975668B1 (https=)
JP (1) JP2001521386A (https=)
KR (1) KR100522289B1 (https=)
CN (1) CN1178955C (https=)
AR (1) AR012427A1 (https=)
AT (1) ATE326481T1 (https=)
AU (1) AU743400B2 (https=)
BR (1) BR9811462A (https=)
CA (1) CA2289476A1 (https=)
CZ (1) CZ9903657A3 (https=)
DE (1) DE69834556T2 (https=)
DK (1) DK0975668T3 (https=)
EE (1) EE9900461A (https=)
ES (1) ES2264569T3 (https=)
HR (1) HRP980203B1 (https=)
HU (1) HUP0001930A3 (https=)
IL (1) IL132281A0 (https=)
NO (1) NO995002L (https=)
NZ (1) NZ337955A (https=)
PL (1) PL194221B1 (https=)
RU (1) RU2241715C2 (https=)
SI (1) SI0975668T1 (https=)
SK (1) SK285639B6 (https=)
TR (1) TR199902562T2 (https=)
TW (1) TW510921B (https=)
UA (1) UA72440C2 (https=)
WO (1) WO1998046642A1 (https=)
ZA (1) ZA983148B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
DK1159003T3 (da) * 1999-03-02 2011-02-07 Centocor Inc Anti-tnfalfa-antistoffer til terapi af steroid-resistent astma
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
US7056512B1 (en) 1999-07-20 2006-06-06 Pharmexa A/S Method for down-regulating GDF-8 activity
EP1296709A1 (en) * 2000-06-21 2003-04-02 Ferring BV Solubilised protein vaccines
AU2003208314A1 (en) * 2002-03-11 2003-09-22 Pharmexa A/S Novel application of vaccination against tnf-alpha
FR2844514B1 (fr) * 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
MXPA05008156A (es) * 2003-02-01 2005-09-30 Neuralab Ltd Inmunizacion activa para generar anticuerpos para beta-a soluble.
MXPA06009805A (es) 2004-02-27 2007-04-02 Vaxconsulting Peptidos de interleucina 1 beta y factor de necrosis tumoral alfa y metodo de tratamiento utilizando los mismos.
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
CN102961746B (zh) 2005-05-16 2016-06-15 艾伯维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
KR20100084623A (ko) * 2007-09-25 2010-07-27 인터벳 인터내셔널 비.브이. 골관절염 치료용 백신
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
KR20120101050A (ko) 2009-11-05 2012-09-12 더 유에이비 리서치 파운데이션 기저형 유전자형 암의 치료 방법
WO2011116344A2 (en) 2010-03-18 2011-09-22 The Uab Research Foundation Targeting cancer stem cells
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
WO2012076668A1 (en) 2010-12-08 2012-06-14 Neovacs Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
CN102539778A (zh) * 2010-12-24 2012-07-04 北京义翘神州生物技术有限公司 一种检测人肿瘤坏死因子-α的酶联免疫试剂盒
JP2011201902A (ja) * 2011-05-19 2011-10-13 Wyeth Llc 可溶性A−βに対する抗体を生成させるための能動免疫
CN103376327A (zh) * 2012-04-28 2013-10-30 通用电气公司 检测抗体或融合蛋白的浓度的方法
EP3292140B1 (en) 2015-05-05 2022-04-20 Rubicon Biotechnology LLC Cancer immunotherapeutic
CN106279403B (zh) * 2016-08-16 2019-06-11 长春市海兰深生物医学技术有限公司 一种检测天然肺癌相关抗体的组合物、试剂盒和方法
CN106478802B (zh) * 2016-10-11 2019-08-09 浙江省人民医院 TNF-α蛋白B细胞表位,含此表位的多抗原肽及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3750056T2 (de) 1986-06-20 1995-04-06 Dainippon Pharmaceutical Co Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS.
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU634379B2 (en) 1991-04-29 1993-02-18 Csl Limited Recombinant immunocastration vaccine
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden

Similar Documents

Publication Publication Date Title
JP2000509942A5 (https=)
JP2000509637A5 (https=)
JP2000507042A5 (https=)
JP2000509912A5 (https=)
JP2000509635A5 (https=)
JP2000510751A5 (https=)
JP2000509587A5 (https=)
JP2000507369A5 (https=)
JP2000507433A5 (https=)
JP2000508866A5 (https=)
JP2000510793A5 (https=)
JP2000508022A5 (https=)
JP2000508841A5 (https=)
JP2000508680A5 (https=)
JP2000509804A5 (https=)
JP2000509853A5 (https=)
JP2000509755A5 (https=)
JP2000510969A5 (https=)
JP2000510247A5 (https=)
JP2000508836A5 (https=)
JP2000508102A5 (https=)
JP2000509520A5 (https=)
JP2000509818A5 (https=)
JP2000507434A5 (https=)
JP2000508880A5 (https=)